🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I just uncovered my long-ago musings in this blast from the past (Nov. 24, 2008): Top 10 Reasons Why It’s So Much Better to be a Private Biotech Company Unfortunately, so much rings true today...

Odds of FDA missing the PDUFA deadline?

Case in point: Cargo Therapeutics $CRGX Cargo has become another kind of biotech test case: What to do with a cash-rich company after its lead asset — the only reason investors backed the company in the first place — blows up? SHUT IT DOWN! statnews.com/2025/02/20/why…

Shutting down public zombies is of course an option. But wind-down has its own costs and can "waste" the value of (1) public listing; (2) carefully assembled team; (3) back-up assets. Public market investors by default are trusting Boards of Directors to make the "right" choice.

So, recently-promoted FDA employees are being laid off because they become officially "provisional" at that point? Uh, wouldn't your recently promoted employees absolutely be some of your high-achieving, best-and brightest?

Interesting to be sure, but I'd have thought the "Head of Data Science at Blue Rose Research" would have a better understanding of what "increased by ~1.5X" actually means...

Great series of posts. I'd point out that while making low-value intros can indeed damage relationships, making high-value intros can score points with both sides -- and it can be a way of re-establishing contact with long-lost friends...

Two of the absolute best heads of hair in the biotech biz right there, folks! (And zero offense meant to the gentleman on the right.)

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: Alta Partners' Managing Director Bob More shares his take on biotech and his philosophy of investing in people. Full video: biotechtv.com/post/bob-more-…

Media star! 😀

Just seeing this. I assume it was a short segment.😟

StubHub going public... Wonder if they complained to their investment banks that the fees were too high???

I hear you, but it would have been nice if Harvard had found another hill to die on than defending antisemitism.

Thanks to Endpoints News for posting the exact wording of the "pill penalty" Executive Order. Everyone seems to believe this means lengthening the time for small molecules before Medicare price negotiation. Great! But is there any worry this could be achieved by shortening biologics?

Surely meant to be "provocative," but what do I have better to do on a rainy Sunday than post an all-too-brief, point-by-point response?

Not surprised (unfortunately) by the first paragraph below from PitchBook News regarding biotech-focused VC funds, but the second paragraph is still impressive.

Great job by Jake Becraft and really exciting data - but who's that Brad-poster with an open-collared shirt???

Insert Adam Feuerstein ✡️ sarcasm emoji here?

Hmmm... The term "IPO" sounds familiar from my biotech past... but I can't quite place it...

Must-listen episode this week that literally brings DMD to life... just wow... Sure seems like FDA needs to figure out a way to allow elevidys back on the market, at least perhaps for boys who are already responding (and with appropriate warnings). Damn.